BioLineRx (TASE:BLRX) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

BLRX Stoklara Genel Bakış

Ticari aşamada bir biyofarmasötik şirketi olan BioLineRx Ltd. onkoloji ve nadir hastalıklar için terapötikler geliştirmekte ve ticarileştirmektedir.

Şirket hakkında

BLRX temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 92.5% daha düşük bir oranda işlem görüyor

Gelirin yılda 28.04% oranında artması öngörülüyor

Risk Analizi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Hissedarlar geçen yıl sulandırıldı

Anlamlı bir piyasa değeri yok ( ₪184M )

BioLineRx Ltd. Rakipler

Evogene

TASE:EVGN

₪62.4m

PlantArc Bio

TASE:PLNT

₪6.9m

Can-Fite BioPharma

TASE:CANF

₪53.1m

Kamada

TASE:KMDA

₪1.1b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti BioLineRx
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	₪0.14
52 Haftanın En Yüksek Seviyesi	₪0.44
52 Haftanın En Düşük Seviyesi	₪0.14
Beta	0.80
11 Aylık Değişim	-15.38%
3 Aylık Değişim	-3.38%
1 Yıllık Değişim	-61.04%
33 Yıllık Değişim	-75.17%
5 Yıllık Değişim	-78.43%
Halka arzdan bu yana değişim	-99.78%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	BLRX	IL Biotechs	IL Pazar
7D	-12.8%	-0.8%	0.1%
1Y	-61.0%	-12.0%	7.6%

Getiri vs. Endüstri: BLRX geçen yıl % -18.7 oranında getiri sağlayan IL Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: BLRX geçen yıl % 3.2 oranında getiri sağlayan IL Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is BLRX's price volatile compared to industry and market?
BLRX volatility
BLRX Average Weekly Movement	8.9%
Biotechs Industry Average Movement	7.2%
Market Average Movement	4.3%
10% most volatile stocks in IL Market	7.1%
10% least volatile stocks in IL Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: BLRX hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: BLRX 'nin haftalık oynaklığı ( 9% ) geçen yıl boyunca sabit kaldı, ancak hala IL hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2003	79	Phil Serlin	www.biolinerx.com

Ticari aşamada bir biyofarmasötik şirketi olan BioLineRx Ltd. onkoloji ve nadir hastalıklar için terapötikler geliştirmekte ve ticarileştirmektedir. Şirketin boru hattı, orak hücre hastalığının tedavisi için Faz 1 klinik çalışmasında olan bir peptit olan APHEXDA'yı (motixafortide) ve pankreas kanserinin tedavisi için Faz 2b klinik çalışmasının yanı sıra multipl miyelom tedavisi için tamamlanmış Faz 3 klinik çalışmasını içermektedir.

BioLineRx Ltd. Temel Bilgiler Özeti

BioLineRx'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
BLRX temel i̇stati̇sti̇kler
Piyasa değeri	₪183.58m
Kazançlar(TTM)	-₪114.81m
Gelir(TTM)	₪64.99m

2.6x

P/S Oranı

-1.5x

F/K Oranı

BLRX aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
BLRX gelir tablosu (TTM)
Gelir	US$17.05m
Gelir Maliyeti	US$6.04m
Brüt Kâr	US$11.00m
Diğer Giderler	US$41.12m
Kazançlar	-US$30.12m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.025
Brüt Marj	64.55%
Net Kâr Marjı	-176.67%
Borç/Özkaynak Oranı	210.6%

BLRX uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

BLRX Stoklara Genel Bakış

Ödüller

Risk Analizi

BioLineRx Ltd. Rakipler

TASE:EVGN

₪62.4m

TASE:PLNT

₪6.9m

TASE:CANF

₪53.1m

TASE:KMDA

₪1.1b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

New major risk - Revenue and earnings growth

BioLineRx Ltd., Annual General Meeting, Oct 01, 2024

BioLineRx Ltd. to Report Q2, 2024 Results on Aug 15, 2024

BioLineRx Ltd Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications in Sickle Cell Disease

New major risk - Financial position

BioLineRx Ltd. Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer at American Society of Clinical Oncology

Recent updates

New major risk - Revenue and earnings growth

BioLineRx Ltd., Annual General Meeting, Oct 01, 2024

BioLineRx Ltd. to Report Q2, 2024 Results on Aug 15, 2024

BioLineRx Ltd Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications in Sickle Cell Disease

New major risk - Financial position

BioLineRx Ltd. Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer at American Society of Clinical Oncology

BioLineRx Ltd. to Report Q1, 2024 Results on May 28, 2024

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

Does BioLineRx (TLV:BLRX) Have A Healthy Balance Sheet?

New major risk - Share price stability

New major risk - Revenue and earnings growth

BioLineRx Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (Bl-8040) Suitable for Large Scale Production

Biolinerx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer

BioLineRx Ltd. Announces Acceptance of Two Poster Presentations on APHEXDA®? (Motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT®?

New minor risk - Market cap size

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

BioLineRx Ltd. Appoints Gal Cohen to Its Board as a Class I Director

New major risk - Shareholder dilution

BioLineRx Ltd. to Report Q3, 2023 Results on Nov 20, 2023

New minor risk - Shareholder dilution

BioLineRx Ltd. announced that it has received $14.6 million in funding

New minor risk - Market cap size

Biolinerx Ltd. Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (Pdac)

BioLineRx Ltd Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma

New major risk - Financial position

BioLineRx (TLV:BLRX) Has Debt But No Earnings; Should You Worry?

BioLineRx Ltd. to Report Q2, 2023 Results on Aug 30, 2023

BioLineRx Ltd. Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase

BioLineRx Ltd., Annual General Meeting, Aug 07, 2023

BioLineRx Ltd. to Report Q1, 2023 Results on May 24, 2023

Health Check: How Prudently Does BioLineRx (TLV:BLRX) Use Debt?

Rosen Law Firm Encourages Biolinerx Ltd. Investors with Losses to Secure Counsel Before Important Deadline

Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of BioLineRx Ltd

BioLineRx Ltd. Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer

BioLineRx Ltd. Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors

Less than half of directors are independent

BioLineRx Ltd. Announces U.S. FDA Acceptance of New Drug Application for Aphexda® (Motixafortide) in Stem Cell Mobilization

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

Biolinerx Ltd. Announces U.S. Commercialization Plan for Aphexda (Motixafortide) in Stem Cell Mobilization

BioLineRx Announces Submission of New Drug Application to U.S. Food and Drug Administration for Motixafortide in Stem Cell Mobilization

BioLineRx Ltd. to Report Q2, 2022 Results on Aug 16, 2022

BioLineRx Ltd. Appoints Holly W. May as its Chief Commercial Officer

Is BioLineRx (TLV:BLRX) A Risky Investment?

BioLineRx Ltd., Annual General Meeting, Jul 03, 2022

BioLineRx Ltd. to Report Q1, 2022 Results on May 11, 2022

Less than half of directors are independent

BioLineRx Ltd. Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization

Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

BioLineRx Announces Completion of Enrollment of Phase 1/2A Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid Tumors

BioLineRx Ltd. Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patients

Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

Forecast breakeven pushed back to 2024

BioLineRx Ltd. Announces Positive Top-Line Results from GENESIS Phase 3 Trial of Motixafortide in Stem-Cell Mobilization for Autologous Bone Marrow Transplantation in Multiple Myeloma Patients

BioLineRx Ltd. to Report Fiscal Year 2020 Results on Feb 23, 2021

New 90-day high: ₪0.82

BioLineRx Ltd. Announces Final Results from Phase 2a COMBAT/KEYNOTE-202 Triple Combination Study of Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)

New 90-day high: ₪0.66